Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports.
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results